ALPHARETTA, Ga.--(BUSINESS WIRE)--SANUWAVE Health, Inc. (OTCBB: SNWV) (www.sanuwave.com), an emerging medical technology company focused on the development and commercialization of non-invasive, biological response activating devices in regenerative medicine, today announced positive top-line results from the Company’s pivotal Phase III, Investigational Device Exemption (IDE) clinical trial comparing dermaPACE™ to sham control (non-active treatment), when both are combined with the current standard of care for the treatment of diabetic foot ulcers. Diabetic foot ulcers are an area of significant unmet medical need and represent a $2 billion market in the U.S. alone.
